

**Block view of the study programme**

Or Th Pr Au Cr

**Block 1**
**Information**

Professor Ph HUBERT

Analytical chemistry

B36 - 4000 Liege

Phone number: 04/366 43 16

e-mail address: Ph.Hubert@uliege.be

**Collegiality**

For ULiege: Vincent BIERLAIRE, Bruno BOULANGER, Raphaël DENOZ, Laurence DENIS, Brigitte EVRARD, Marianne FILLET, Michel FREDERICH, Philippe HUBERT, Roland MARINI, Dominique MARTIN, Bernard PIROTTE, Régis RADERMECKER, Jean-Michel VANDERHOFSTADT, Eric ZIEMONS.

For ULB: Patrick DI STEFANO, François DUFASNE, Walid EL AZAB, Véronique FONTAINE, Jonathan GOOLE, Anne LENAERS, Hugues MALONNE, Thierry SCHURMANS, Caroline STEVIGNY, Pierre VAN ANTWERPEN, Francis VANDERBIST, Karen VAN MALDEREN, David VERMIJLEN, Zéna WIMANA.

For UCLouvain: Catherine DRUEZ, Laure ELENIS, Xavier MARCELIS, François-Xavier MATHY, Jacques POUPAERT, Thierry PRONCE, Joëlle LECLERCQ, Nevin SERBEST, Rita VANBEVER.

**Compulsory courses**

Course ID	Course Name	TA	Th	Pr	Au	Cr	
PHIN2034-1	<i>Biotechnologies</i>					<b>7</b>	
	- Concepts and production of protein and oligonucleotide biopharmaceuticals - David VERMIJLEN	15	-	-			
	- Living biopharmaceuticals, vaccines and biosecurity - Véronique FONTAINE	6	-	-			
	- Managing the risk of the release of cell and genetic products - Roland MARINI DJANG'EING'A	3	-	-			
	- Formulation of biopharmaceuticals - Rita VANBEVER	15	-	-			
	- Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part A - Marianne FILLET	5	-	-			
	- Quality control and analytical techniques in biopharmaceuticals, good practice and legal recommendations, part B (post-translational modifications) - Cédric DELPORTE	3	-	-			
	- From the laboratory to the pharmacy: legal requirements - part a: Patents and industrial protection - Patrick DI STEFANO	5	-	-			
	- From the laboratory to the pharmacy: legal requirements - part b: Statutes and regulatory constraints on biological products - Hugues MALONNE	3	-	-			
	- From the laboratory to the pharmacy: legal requirements - part c: Procedure for releasing batches and the legal framework of vaccines - Lorenzo TESOLIN	1	-	-			
	- From the laboratory to the pharmacy: legal requirements - part d: Organisation of quality assurance - Thierry PRONCE	3	-	-			
	- From the laboratory to the pharmacy: legal requirements - part e: Introduction to Biobanking - Stéphanie GOFFLOT	3	-	-			
	PHIN2004-1	<i>Active substances</i>					<b>4</b>
		- Substances issues de recherches pharmacochimiques, part a - Bernard PIROTTE	10	-	-		
- Substances issues de recherches pharmacochimiques, part b - François DUFASNE		5	-	-			
- Substances d'origine naturelle, part a - Joëlle LECLERCQ		5	-	-			
- Substances d'origine naturelle, part b - Caroline STEVIGNY		5	-	-			
- Produits radiopharmaceutiques - Zéna WIMANA	10	-	-				
PHIN2008-2	<i>Clinical viewpoints</i>					<b>5</b>	
	- Métabolisme des médicaments et paramètres pharmacocinétiques - FrançoisXavier MATHY	20	-	-			
	- Aspects théoriques et pratiques des études cliniques (y compris les méthodes statistiques appliquées aux études cliniques) - Régis RADERMECKER	15	-	-			

	- <i>Information et pharmacovigilance</i> - Raphaël DENOZ	10	-	-	
PHIN2013-2	<i>Quality assurance and pharmaceutical management</i>	TA			<b>7</b>
	- <i>Principles of pharmaceutical management</i> - JeanMichel VAN DER HOFSTADT	10	-	-	
	- <i>Quality assurance, part a : basic concepts and quality assurance organisation</i> - Thierry PRONCE	14,5	-	-	
	- <i>Quality assurance, part b: analytical technology of procedures and risk analysis</i> - Xavier MARCELIS	10	-	-	
	- <i>English applied to the pharmaceutical industry</i> - Jacques POUPAERT, Nevin SERBEST	20	-	-	
	- <i>Pharmaceutical marketing</i> - Vincent BIERLAIRE	7,5	-	-	
PHIN2033-1	<i>Pharmaceutical technology</i>	TA			<b>5</b>
	- <i>Industrial pharmaceutical microbiology</i> - Véronique FONTAINE	9	-	-	
	- <i>Preformulation and selection of galenical forms</i> - Jonathan GOOLE	15	-	-	
	- <i>Industrial production of galenical forms</i> - Brigitte EVRARD	15	-	-	
	- <i>Industrial aspects of technological development including packaging</i> - Laurence DENIS	10	-	-	
PHIN2023-1	<i>Drug analysis</i>	TA			<b>6</b>
	- <i>Analytical control practices and pharmaceutical and biopharmaceutical control - part a</i> - Pierre VAN ANTWERPEN	7	-	-	
	- <i>Analytical control practices and pharmaceutical and biopharmaceutical control - part b</i> - Marianne FILLET	5	-	-	
	- <i>Pharmaceutical and biopharmaceutical analytical methods - Approving and certifying equipment</i> - Philippe HUBERT, Roland MARINI DJANG'EING'A	12	-	-	
	- <i>Pharmaceutical and biopharmaceutical analytical methods - Process Analytical Technology</i> - Eric ZIEMONS	5	-	-	
	- <i>Statistical methods applied to the pharmaceutical industry</i> - Laure ELENS	15	-	-	
	- <i>Experimental planning and quality by design</i> - Bruno BOULANGER, Pierre LEBRUN	10	-	-	
PHIN2029-2	<i>Regulation and the medical-social environment</i>	TA			<b>8</b>
	- <i>Economic aspects of drug development</i> - Dominique MARTIN	10	-	-	
	- <i>Legislation and procedures applied to pharmaceutical industry</i> - Catherine DRUEZ	10	5	-	
	- <i>Patents and protection</i> - Patrick DI STEFANO	5	-	-	
	- <i>Macroeconomic environment and pharmaco-economics</i> - Hugues MALONNE	7	-	-	
	- <i>CTD File (Common Technical Document)</i> - Walid EL AZAB	15	-	-	
	- <i>Regulations of preclinical and clinical studies, part a : pharmaceutical toxicological files</i> - Karen VAN MALDEREN	7,5	-	-	
	- <i>Regulations of preclinical and clinical studies, part b : clinical studies</i> - Anne LENAERS	5	-	-	
	- <i>Regulations of preclinical and clinical studies, part c : pediatric studies</i> - Thierry SCHURMANS	2,5	-	-	
	- <i>Specific regulatory issues, part a : medicine and herbal dietary supplement</i> - Michel FREDERICH	5	-	-	
	- <i>Aspects réglementaires particuliers, partim b : Préformulation et documentation du développement galénique</i> - Francis VANDERBIST	5	-	-	
PHIN2032-1	<i>Visits and seminars organised in the pharmaceutical industry</i> - François DUFRASNE, Marianne FILLET, Joëlle LECLERCQ, Rita VANBEVER - [75h Vis.]	TA	-	-	[+] <b>3</b>
MTFE2000-1	<i>End-of-course work carried out during an internship in the pharmaceutical industry or in a university research lab</i> - François DUFRASNE, Philippe HUBERT, Joëlle LECLERCQ	TA	-	-	<b>15</b>